EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY-NC 3.0

Phase 2a, Randomized Trial of Mitiperstat Versus Placebo in Patients with COPD at High Risk of Exacerbation (CRESCENDO)

Rod Hughes, Wayne Brailsford, João Ferreira, James D Chalmers, Maria G Belvisi iD, Janwillem W H Kocks iD, Pauline Masters, Paul Thomson, Dawid Łyżwa, Sanna Rosengren, Jason David Cooper, Richard E K Russell und 1 weitere

International Journal of Chronic Obstructive Pulmonary Disease · 2025-09 · Volume 20 · 3305-3315

DOI: 10.2147/copd.s524775 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift International Journal of Chronic Obstructive Pulmonary Disease, 2025-09. Verfasst von Rod Hughes und 12 weiteren Autor:innen. Beteiligte Einrichtung: Respiratory and Immunology Biometrics and Statistical Innovation, AstraZeneca, Cambridge, UK. Hauptthemen laut MEDLINE: Pulmonary Disease, Chronic Obstructive, Lung, Peroxidase, Enzyme Inhibitors. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pulmonary Disease, Chronic ObstructiveLungPeroxidaseEnzyme InhibitorsAnti-Inflammatory AgentsHumansAgedDouble-Blind MethodMiddle AgedDisease ProgressionTreatment OutcomeMaleAged, 80 and overFemaleAdultTime FactorsClinical Trials, Phase II as TopicRandomized Controlled Trials as TopicMulticenter Studies as TopicForced Expiratory VolumeOxidative StressRisk Factors

Stichwörter der Autor:innen

airway neutrophiliaexacerbations of COPDinflammationmyeloperoxidaseneutrophilstreatment for COPD

Substanzen

PeroxidaseEnzyme InhibitorsAnti-Inflammatory Agents

Autor:innen und Institutionen

  • Respiratory and Immunology Biometrics and Statistical Innovation, AstraZeneca, Cambridge, UK.
  • Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
  • Division of Respiratory Medicine and Gastroenterology, University of Dundee, Dundee, UK.
  • Respiratory Pharmacology Group, National Heart & Lung Institute, Imperial College London, London, UK.
  • General Practitioners Research Institute, Groningen, the Netherlands.
  • Observational and Pragmatic Research Institute, Singapore.

ORCID-Profile: Maria G Belvisi, Janwillem W H Kocks

Zitieren

APA

Hughes, R., Brailsford, W., Ferreira, J., Chalmers, J. D., Belvisi, M. G., Kocks, J. W. H., Masters, P., Thomson, P., Łyżwa, D., Rosengren, S., Cooper, J. D., Russell, R. E. K., & Saralaya, D. (2025). Phase 2a, Randomized Trial of Mitiperstat Versus Placebo in Patients with COPD at High Risk of Exacerbation (CRESCENDO). International Journal of Chronic Obstructive Pulmonary Disease, Volume 20, 3305-3315. https://doi.org/10.2147/copd.s524775

Vancouver

Hughes R, Brailsford W, Ferreira J, Chalmers JD, Belvisi MG, Kocks JWH, et al. Phase 2a, Randomized Trial of Mitiperstat Versus Placebo in Patients with COPD at High Risk of Exacerbation (CRESCENDO). International Journal of Chronic Obstructive Pulmonary Disease. 2025;Volume 20:3305-3315. doi:10.2147/copd.s524775

BibTeX
@article{Hughes2025,
  author = {Hughes, Rod and Brailsford, Wayne and Ferreira, João and Chalmers, James D and Belvisi, Maria G and Kocks, Janwillem W H and Masters, Pauline and Thomson, Paul and Łyżwa, Dawid and Rosengren, Sanna and Cooper, Jason David and Russell, Richard E K and Saralaya, Dinesh},
  title = {Phase 2a, Randomized Trial of Mitiperstat Versus Placebo in Patients with COPD at High Risk of Exacerbation (CRESCENDO)},
  journal = {International Journal of Chronic Obstructive Pulmonary Disease},
  year = {2025},
  volume = {Volume 20},
  pages = {3305--3315},
  doi = {10.2147/copd.s524775}
}
Kostenlos starten →